U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Jobs and Training at FDA
  4. Scientific Internships, Fellowships / Trainees and Non-U.S. Citizens
  5. FDA Pharmacy Student Experiential Program
  6. FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors - October 24, 2023
  1. FDA Pharmacy Student Experiential Program

FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors - October 24, 2023

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!

On Tuesday, October 24, 2023, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors. This presentation focused on the importance of medications used for opioid use disorder and provided an overview of FDA's postmarket surveillance process related to medication errors. The presenters discussed medication errors identified for naltrexone injectable suspension, actions to mitigate those errors, and highlighted the importance of the healthcare provider's role in drug safety.

Register Here: FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors

Download Presentation Slides: FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors (PDF - 2.42MB )

Activity Outline and Continuing Education Information

Resources

 
Back to Top